Literature DB >> 12431470

The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition.

G Singh-Ranger1, K Mokbel.   

Abstract

The cyclooxygenase (COX) enzyme system is composed of two isoenzymes, COX-1 and COX-2. Recent sources of experimental and epidemiological evidence suggest a significant role for the COX enzymes, particularly COX-2, in the pathogenesis of breast cancer. This has important implications for treatment of the disease. This article reviews the evidence for a relationship between the COX enzyme system and mammary carcinogenesis, and discusses the likely therapeutic roles and potential pitfalls of COX inhibition.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12431470     DOI： 10.1053/ejso.2002.1329

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN： 0748-7983            Impact factor:   4.424


  14 in total

1.  Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.

Authors:  Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Bhaskar V S Kallakury; Catalin Marian; David S Goerlitz; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Causes Control       Date:  2011-04-23       Impact factor: 2.506

Review 2.  Novel agents for chemoprevention, screening methods, and sampling issues.

Authors:  Mary Jo Fackler; Ella Evron; Seema A Khan; Saraswati Sukumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

3.  Lack of association between cyclooxygenase 2-765G/C gene polymorphism and breast cancer risk in Ahvaz, west-south Iran.

Authors:  Behnaz Ahmadi; Abdolrahim Nikzamir; Seid Mohamadali Ghafari; Ghorban Mohamadzadeh; Mahmod Latifi; Ahmad Bafandeh; Mohammad Fathi; Mir Saeed Yekaninejad; Mahfam Nikzamir
Journal:  Mol Biol Rep       Date:  2014-01-09       Impact factor: 2.316

4.  Expression of COX-2 and HER-2/neu and estrogen and progesterone receptor in primary squamous cell carcinomas of the endometrium.

Authors:  L-C Horn; S Faber; K Bilek; C Leo
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-14       Impact factor: 4.553

5.  Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.

Authors:  K P O'Brien; S Khan; K E Gilligan; H Zafar; P Lalor; C Glynn; C O'Flatharta; H Ingoldsby; P Dockery; A De Bhulbh; J R Schweber; K St John; M Leahy; J M Murphy; W M Gallagher; T O'Brien; M J Kerin; R M Dwyer
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

6.  Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2.

Authors:  Karin Müller-Decker; Irina Berger; Karin Ackermann; Volker Ehemann; Svetlana Zoubova; Sebastian Aulmann; Walter Pyerin; Gerhard Fürstenberger
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

7.  Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2.

Authors:  Dong-Sheng Huang; Ke-Zhen Shen; Jian-Feng Wei; Ting-Bo Liang; Shu-Sen Zheng; Hai-Yang Xie
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

8.  Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study.

Authors:  Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Bhaskar V S Kallakury; Catalin Marian; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Causes Control       Date:  2010-05-25       Impact factor: 2.506

9.  What Is "Enhanced Recovery," and How Can I Do It?

Authors:  Bradford J Kim; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2017-10-24       Impact factor: 3.452

Review 10.  Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?

Authors:  Charles J Rosser; Micah Gaar; Stacy Porvasnik
Journal:  BMC Cancer       Date:  2009-07-09       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.